Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $368.92 million. The enterprise value is $734.99 million.
| Market Cap | 368.92M |
| Enterprise Value | 734.99M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 63.83 million shares outstanding. The number of shares has increased by 2.02% in one year.
| Shares Outstanding | 63.83M |
| Shares Change (YoY) | +2.02% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 11.41% |
| Owned by Institutions (%) | 67.33% |
| Float | 23.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 19.08 |
| PS Ratio | 0.71 |
| Forward PS | 0.66 |
| PB Ratio | 2.15 |
| P/FCF Ratio | 133.86 |
| PEG Ratio | 2.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.00, with an EV/FCF ratio of 266.69.
| EV / Earnings | n/a |
| EV / Sales | 1.41 |
| EV / EBITDA | 10.00 |
| EV / EBIT | 35.32 |
| EV / FCF | 266.69 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 2.28.
| Current Ratio | 1.53 |
| Quick Ratio | 0.87 |
| Debt / Equity | 2.28 |
| Debt / EBITDA | 5.32 |
| Debt / FCF | 141.96 |
| Interest Coverage | 0.50 |
Financial Efficiency
Return on equity (ROE) is -12.30% and return on invested capital (ROIC) is -4.50%.
| Return on Equity (ROE) | -12.30% |
| Return on Assets (ROA) | -2.70% |
| Return on Capital (ROIC) | -4.50% |
| Revenue Per Employee | $525,370 |
| Profits Per Employee | -$21,759 |
| Employee Count | 995 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.95 |
Taxes
In the past 12 months, Bioventus has paid $1.14 million in taxes.
| Income Tax | 1.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +106.43% in the last 52 weeks. The beta is 0.89, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +106.43% |
| 50-Day Moving Average | 5.68 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 45.69 |
| Average Volume (20 Days) | 696,624 |
Short Selling Information
The latest short interest is 567,205, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 567,205 |
| Short Previous Month | 591,325 |
| Short % of Shares Out | 0.89% |
| Short % of Float | 2.42% |
| Short Ratio (days to cover) | 1.69 |
Income Statement
In the last 12 months, Bioventus had revenue of $522.74 million and -$21.65 million in losses. Loss per share was -$0.34.
| Revenue | 522.74M |
| Gross Profit | 342.65M |
| Operating Income | -25.30M |
| Pretax Income | -20.51M |
| Net Income | -21.65M |
| EBITDA | 73.49M |
| EBIT | 20.81M |
| Loss Per Share | -$0.34 |
Balance Sheet
The company has $25.17 million in cash and $391.24 million in debt, giving a net cash position of -$366.07 million or -$5.74 per share.
| Cash & Cash Equivalents | 25.17M |
| Total Debt | 391.24M |
| Net Cash | -366.07M |
| Net Cash Per Share | -$5.74 |
| Equity (Book Value) | 171.28M |
| Book Value Per Share | 2.68 |
| Working Capital | 92.58M |
Cash Flow
In the last 12 months, operating cash flow was $6.85 million and capital expenditures -$4.09 million, giving a free cash flow of $2.76 million.
| Operating Cash Flow | 6.85M |
| Capital Expenditures | -4.09M |
| Free Cash Flow | 2.76M |
| FCF Per Share | $0.04 |
Margins
Gross margin is 65.55%, with operating and profit margins of -4.84% and -4.14%.
| Gross Margin | 65.55% |
| Operating Margin | -4.84% |
| Pretax Margin | -3.92% |
| Profit Margin | -4.14% |
| EBITDA Margin | 14.06% |
| EBIT Margin | 3.98% |
| FCF Margin | 0.53% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.02% |
| Shareholder Yield | -2.02% |
| Earnings Yield | -5.87% |
| FCF Yield | 0.75% |
Analyst Forecast
The average price target for Bioventus is $8.50, which is 47.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 47.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 0.69 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.69 |
| Piotroski F-Score | 5 |